|
|
|
|
|
|
|
|
131st MAINE LEGISLATURE |
|
|
LD 1829 |
|
LR 735(02) |
|
|
|
An Act to Reduce
Prescription Drug Costs by Requiring Reference-based Pricing |
|
Fiscal Note for
Bill as Amended by Committee Amendment " " |
|
Committee: Health Coverage, Insurance and
Financial Services |
|
Fiscal Note Required: Yes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Note |
|
|
|
|
|
|
|
|
|
|
FY 2023-24 |
FY 2024-25 |
Projections FY 2025-26 |
Projections FY 2026-27 |
Net Cost
(Savings) |
|
|
|
|
|
|
General Fund |
|
$0 |
$1,336,343 |
$1,147,961 |
$1,160,160 |
|
|
|
|
|
|
|
Appropriations/Allocations |
|
|
|
|
|
|
General Fund |
|
$0 |
$1,336,343 |
$1,147,961 |
$1,160,160 |
|
|
|
|
|
|
|
Fiscal Detail
and Notes |
|
|
|
|
|
|
This bill expands
the charter of the Prescription Drug Affordability Board (PDAB) and directs
the board to assess strategies to reduce prescription drug costs and to take
steps to implement reference-based pricing. There are many changes that could
be identified by the PDAB, such as, setting upper payment limits,
referenced-based pricing or potential regulation of prescription drug
cost-sharing requirements. The bill includes General Fund appropriations to
the Office of Affordable Health Care of $1,336,343 in fiscal year 2024-25 to
establish one Public Service Coordinator II position, one Planner II position
and for contracts to administer the new requirements of the Maine
Prescription Drug Affordability Board. |
|
The potential
changes identified in the bill would have a large future biennium impact to
the State Employee Health Plan, but it is not known at this time which, if
any, of these changes may be made by the PDAB and the potential future impact
to the SEHP cannot be determined at this time. |
|
|
|
|
|
|
|